This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as a first-line treatment for some advanced triple-negative breast cancers (TNBC). Specifically, the recommendation is for adult patients with…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
CHMP Recommends Expanding Imbruvica Use in the EU to Include 2 New Cancer Regimens
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the expansion of the current marketing authorization for Imbruvica (ibrutinib) to include two new indications in the European Union. The first indication is to be used in combination with…
DPX-Survivac-Keytruda Trio Shows Promise in DLBCL Patients
This post was originally published on this site IMV‘s lead candidate, DPX-Survivac, in combination with Keytruda (pembrolizumab) and low-dose intermittent cyclophosphamide, eliminated radiologic traces of cancer cells in one-third of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients in a Phase 2 trial, the company announced. The findings from SPiReL (NCT03349450) were shared at the…
Survival Is All About the Money
This post was originally published on this site “It’s cancer,” my friend said. She had seen a doctor for something unrelated, but now she’s freaking out. Mostly about the money. The tumor they found in her right breast is small, but it’s rocking her world. “I can’t afford time off work,” she said. “And I…
Phase 3 Trial of Topsalysin, Potential Treatment for Localized Prostate Cancer, Planned for Europe
This post was originally published on this site The European Medicines Agency (EMA) has approved Sophiris Bio’s design for a Phase 3 trial to evaluate the potential of topsalysin (PRX302), an investigative agent for localized prostate cancer. The trial plans to enroll 700 men with intermediate risk disease, who will be randomized to either a…
Testing for Multiple Biomarkers at a Time Can Increase Early Detection of OC
This post was originally published on this site Testing for additional biomarkers along with the well-known biomarker CA125 can improve the detection of early-stage ovarian cancer, a new study shows. The blood-based assay could significantly improve patient survival if ovarian cancers are identified earlier. The study, “Simultaneous Measurement of 92 Serum Protein Biomarkers for the…
FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid (lenalidomide) and dexamethasone, to treat patients newly diagnosed with multiple myeloma who are ineligible to receive an autologous stem cell transplant (ASCT). Darzalex is an antibody designed to recognize and block…
Fujifilm Bus Hits the Road to Offer Breast Cancer Screenings and Promote Early Diagnosis
This post was originally published on this site Fujifilm Medical Systems USA has launched a nationwide effort to enhance access to breast cancer screening and raise awareness about the importance of early disease detection. Called “Aspire to Be Fearless,” the 18-month, 48-state campaign features a mobile mammography bus that will travel around the country to…
PARP Inhibitors Used in ‘One-two Punch’ Strategy to Kill OC Cells in Mouse Models, Study Shows
This post was originally published on this site Researchers have developed a two-step approach that harnesses the aging process of cells, allowing breast and ovarian cancers to be effectively targeted and destroyed in cell and mouse preclinical models. The “one-two punch” strategy consists of first treating cancer cells with PARP inhibitors — an anti-cancer therapy…
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
This post was originally published on this site Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed or refractory multiple myeloma, according to updated results of a Phase 2 study. The study, “Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma:…
X4 Pharmaceuticals, LLS Collaborate to Develop Mavorixafor to Treat Waldenström’s Macroglobulinemia
This post was originally published on this site X4 Pharmaceuticals and The Leukemia & Lymphoma Society (LLS) have joined forces to accelerate the development of X4’s lead product candidate, mavorixafor, for the treatment of Waldenström’s macroglobulinemia, a rare form of non-Hodgkin’s lymphoma. Under LLS’ Therapy Acceleration Program (TAP), X4 will conduct a Phase 1/2 clinical…
Complete Remission Induced in B-cell ALL Patients After Single Dose of FasT CAR-19 Therapy, Preliminary Data Show
This post was originally published on this site A single infusion of an experimental cell therapy called FasT CAR-19 was well-tolerated and induced a complete remission in all B-cell acute lymphoblastic leukemia (B-ALL) patients included in a Phase 1 trial, the therapy’s developer, Gracell Biotechnologies, has announced. All patients had received multiple prior lines of…